Chemical Design and Pharmacokinetics Enable Precision Psychedelic Therapeutics.
Anna C. Renner, Robert B. Kargbo
ACS Medicinal Chemistry Letters January 12, 2026 DOI: 10.1021/acsmedchemlett.5c00780 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | Recent patent applications indicate a strategic shift toward chemically and pharmacokinetically precise neurotherapeutics in psychedelic development. |
Abstract
Recent psychedelic patent activity highlights a strategic shift from experiential framing toward chemically and pharmacokinetically precise neurotherapeutics. Four recent patent applications collectively span solid-state control of psilocybin, exposure-shaped intramuscular and infusion-based dosing, and chemically diversified monoaminergic scaffolds with defined transporter and receptor pharmacology. Together, these disclosures outline a platform-level evolution toward reproducible, mechanism-informed psychedelic medicines.
Citations in the library
Cites 5
- Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications Pharmaceuticals January 19, 2025
- Psychedelics and connectedness to natural and social worlds: An examination of the evidence and a proposed conceptual framework. Current Opinion in Psychology April 1, 2025
- Utilizing Psychedelics to Enhance Well-Being: A Systematic Review Journal of Psychoactive Drugs March 31, 2025
- Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives ACS Chemical Neuroscience June 6, 2025
- Psychedelics: The pathway to implementation in the European healthcare systems. European Neuropsychopharmacology December 3, 2025